Functioning as miRNA sponges, long non-coding RNA (lncRNA) exert its pharmacological action via regulating expression of protein-coding genes. However, the lncRNA-mediated ceRNA in cerebral Infarction (CI) remains unclear. In this study, the expression recordsets of mRNA, lncRNA and miRNA of CI samples were obtained from the NCBI GEO datasets separately. The differentially expressed lncRNAs (DELs), miRNAs (DEMis) and mRNAs (DEMs) were identified by limma package in R platform. A total of 267 DELs, 26 DEMis, and 760 DEMs were identified as differentially expressed profiles, with which we constructed the ceRNA network composed of DELs-DEMis-DEMs. Further, clusterProfiler package in R platform is employed for performing Gene Ontology (GO) and KEGG pathway analysis. An aberrant ceRNA network was constructed according to node degrees in CI, including 28 DELs, 19 DEMs and 12 DEMis, from which we extracted the core network, in which 9 nodes were recognized as kernel genes including Tspan3, Eif4a2, rno-miR-208a-3p, rno-miR-194-5p, Pdpn, H3f3b, Stat3, Cd63 and Sdc4. Finally, with the DELs-DEMis-DEMs ceRNA network provided above, we can improve our understanding of the pathogenesis of CI mediated by lncRNA.

In recent years, transdermal drug delivery systems have gained considerable attention for their ability to enhance patient compliance and provide consistent drug release. However, the barrier function of the skin’s outermost layer remains the foremost challenge in these systems. As a result, there is a growing interest in the use of ethosomes as a cutting-edge nanocarrier in drug delivery. This review presents the concept and mechanism of action of ethosomes as well as the numerous types and preparation techniques available. It also discusses the significance of characterization methods and how they impact ethosomal properties along with recent advancements and applications in the realm of transdermal drug delivery. Ethosomes exhibit tremendous potential for the pharmaceutical industry, and optimizing preparation methods, performing comprehensive property studies, and exploring their applications are critical areas for future research.

Immunotherapy has emerged as a transformative paradigm in oncology, yet its clinical efficacy remains constrained by the immunosuppressive tumor microenvironment and inadequate spatiotemporal control of existing modalities, resulting in suboptimal patient response rates and frequent immune‐related adverse events. Stimuli‐responsive biomaterials, capable of precise modulation over the delivery kinetics of immunotherapeutic agents, are validated as powerful strategies for achieving targeted immunomodulation. This review systematically delineates innovative design frameworks for tumor microenvironment (TME)‐responsive nanomaterials leveraging dynamic TME features. Through detailed dissection of cancer‐immunity cycle barriers, including spanning impaired antigen presentation, compromised T cell priming/activation, and defective effector function, breakthrough advances in next‐generation delivery platforms are highlighted that reignite antitumor immunity at a critical juncture. Furthermore, preclinical validation and clinical translation challenges of TME‐responsive nanomaterials are evaluated. Building upon current immunotherapy trends, this review also identifies critical translational determinants, with the aim of bridging the bench‐to‐bedside gap in precision cancer immunotherapy.